Glaucoma is one of the most common causes of blindness, thus seriously affecting people's
health and quality of life. The topical medical therapy is as the first line treatment in the …

Purpose To investigate the intraocular pressure (IOP)-lowering efficacy and tolerance of
brinzolamide/brimonidine fixed combination (BBFC) under real-life conditions in a tertiary …

Purpose To determine the intraocular pressure (IOP)-lowering effect of fixed-combination
brinzolamide 1%/brimonidine 0.2%(BBFC) over a 24-hour period. Design Prospective …

We evaluated glaucoma patients for the efficacy, safety and satisfaction associated with
switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of …

Objective To describe the safety and effectiveness of CyPass supraciliary microstent
implantation alone in eyes with open-angle glaucoma (OAG) followed up for up to 3 years …

Introduction Maximal medical therapy (MMT) is the use of≥ 3 classes of topical anti-
glaucoma agents to achieve maximal intraocular pressure (IOP) reduction while minimizing …

Abstract Purpose A brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination
(BBFC) was recently approved for glaucoma and ocular hypertension treatment in Japan …

Objective To evaluate the intraocular pressure (IOP)-lowering effect based on the number of
ingredients and survival rate due to adverse reactions of brinzolamide (1%)/brimonidine …

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily
brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a …

Аннотация В обзоре суммированы результаты современной клинической практики
лечения больных с глаукомой, в которой, как известно, зачастую применяются …